Navigation Links
Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
Date:6/22/2011

CHAPEL HILL, N.C., June 22, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the 2011 Wells Fargo Healthcare Conference at 1 p.m. EDT, June 23, 2011, in Boston.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and other infections and TAKSTA™ for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.

Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners LLC
(212) 845-4251
Tony.russo@russopartnersllc.com


'/>"/>
SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cempra Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
2. Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
3. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
4. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
5. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
7. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
8. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
9. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
11. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... MARLTON, N.J. , Feb. 27, 2015  Acsis ... collaboration and serialization solutions, announced today that John ... as a Supply & Demand Chain Executive ... chain executives who are leading initiatives to help prepare ... challenges of today,s business climate. This year,s list of ...
(Date:2/27/2015)... 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... pro forma net operating loss (NOL) guidance and its ... position.  Isis, significantly improved financial results were due in ... payments the Company received from its partners.  Isis, pro ... nearly 60% improvement over its 2013 NOL of $40.2 ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... May 10, 2011 Omeros Corporation (NASDAQ: ... and commercializing products focused on inflammation, coagulopathies and disorders ... results for the first quarter of 2011. ... ended March 31, 2011 were $7.7 million compared to ...
... 2011 Pierrel Research USA, Inc. ( www.pierrel-research-usa.com ... global pharmaceutical services company ( www.pierrel.it ), announces ... with epinephrine 1:100,000 and Articaine hydrochloride 4% with ... of Articaine with epinephrine, an injectable dental anesthetic ...
Cached Medicine Technology:Omeros Corporation Reports First Quarter 2011 Financial Results 2Omeros Corporation Reports First Quarter 2011 Financial Results 3Omeros Corporation Reports First Quarter 2011 Financial Results 4Pierrel Research USA Launches Orabloc™ a New Purer Articaine 2Pierrel Research USA Launches Orabloc™ a New Purer Articaine 3
(Date:3/1/2015)... 2015 Adults who are not legally ... term or universal policies can now use the QuotesPros.com ... life insurance companies for single adults can now be ... http://quotespros.com/life-insurance.html . , The rate plans that nationwide agencies ... to a number of life protection policies. The term, ...
(Date:3/1/2015)... 01, 2015 A federal court ... ) scheduled to go to trial in October ... witness to provide testimony regarding the role an ... the Profemur device, Bernstein Liebhard LLP comments. According ... Northern District of Iowa on February 25th, Wright ...
(Date:3/1/2015)... March 01, 2015 The number of ... over the past few weeks in two New Jersey ... filing claims, the Firm announces. , A Case ... in the Bergen County proceeding established for products manufactured ... a few weeks earlier, when 90 fewer cases had ...
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:3/1/2015)... 01, 2015 Theme and plugin developers ... transition pack for Final Cut Pro X entitled ... transitions to any FCPX editors project.” Said Christiana Austin, ... the tools needed to easily drag and drop their ... gets many different controls over the parameters of this ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2
... Websites with a Turn-Key Solution for Health Portal ... ... Jan. 16 HealthCare.com,( http://www.healthcare.com ), the leading healthcare provider directory ... MediResource ( http://www.mediresource.com ), a leading creator and,syndicator of interactive health ...
... (TSX:,DAX) (NASDAQ: DRAX ) has received approval from ... Course Issuer Bid (NCIB) to,purchase up to 4,072,054 common ... in the public float as at January 14, 2008.,As ... were issued and,outstanding., Purchases may begin on January ...
... Speeches and Ads During,Presidential Symposium at 2008 Winter ... prior to the primary,elections in the 2008 United ... Westen, Ph.D., will describe the,emotional way in which ... the American Psychoanalytic Association,s 2008 Winter Meeting.,Dr. Westen, ...
... PITTSBURGH, Jan. 16 It,s often hard for,children ... friends, but they,need friendship and play time as ... learn how to help ASD children foster friendships ... by the Hope Learning Center LLC, the conference ...
... directly linked to several diseases such as hypertension and type ... adipose tissues and may form a biochemical link between obesity ... insulin inhibits resistin mRNA level in 3T3-L1, which does not ... play a role in insulin resistance? Is insulin the major ...
... from Universit Lavals Faculty of Medicine and Robert-Giffard Hospital ... of antipsychotic drugswhich in extreme cases can be as ... avoided through a specially designed weight control program. The ... Tremblay report the details of their findings in a ...
Cached Medicine News:Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 2Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 3Health News:DRAXIS Share Buyback Approved by TSX 2Health News:DRAXIS Share Buyback Approved by TSX 3Health News:DRAXIS Share Buyback Approved by TSX 4Health News:2008 Presidential Campaign on the Couch 2Health News:PA Cyber Sponsors Conference on Helping Children With Autism Form Friendships 2Health News:Weight gain induced by antipsychotic drugs can be avoided 2
For the detection of pan specific pLDH, utilizing whole blood samples. Parabank excludes infected blood from the blood supply in the blood bags....
192 Test Enzyme Immunoassay for the detection of Human IgG antibodies to all four forms of Malaria....
ADVANTAGE MALARIA STIX is a visual, rapid and sensitive immunoassay for the qualitative differential detection of P.falciparum (P.f) and P.vivax (P.v) malaria in Human Blood only....
Malaria device / strip (2 line, PAN specific-pLDH)...
Medicine Products: